Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease

Mucosal Immunology

Volumn 8, Issue 4, 2015, Pages 943-958

  Friedrich, M ^a   Diegelmann, J ^a   Schauber, J ^a   Auernhammer, C J ^a   Brand, S ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN DELTA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 17C; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN INDUCED PROTEIN 1; PROTEIN KINASE B; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACT1 PROTEIN; BIOLOGICAL MARKER; CCAAT ENHANCER BINDING PROTEIN; CHROMOGRANIN A; CONNEXIN 43; CYTOKINE; IL23R PROTEIN, HUMAN; INTERLEUKIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDE FRAGMENT; RIBONUCLEASE; TRANSCRIPTION FACTOR; ZC3H12A PROTEIN, HUMAN;

ARTICLE; AUTOCRINE EFFECT; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; GENE EXPRESSION; GOBLET CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IL23R GENE; INFLAMMATORY BOWEL DISEASE; INTERLEUKIN 17C GENE; INTERLEUKIN 23 GENE; INTESTINE EPITHELIUM CELL; NEUROSECRETORY CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TH17 CELL; BLOOD; EPITHELIUM CELL; GENETICS; GENOTYPE; IMMUNOLOGY; METABOLISM; PATHOLOGY; RNA STABILITY;

AUTOCRINE COMMUNICATION; BIOMARKERS; CCAAT-ENHANCER-BINDING PROTEINS; CHROMOGRANIN A; CONNEXIN 43; CYTOKINES; EPITHELIAL CELLS; GENE EXPRESSION; GENOTYPE; GOBLET CELLS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-17; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROENDOCRINE CELLS; NF-KAPPA B; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, INTERLEUKIN; RIBONUCLEASES; RNA STABILITY; RNA, MESSENGER; TH17 CELLS; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84932618204     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2014.124     Document Type: Article

References (57)

1. Brand S. Crohn's disease: Th1, Th17 or both?. The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58, 1152-1167 (2009
2. Monteleone I., Sarra M., Pallone F. & Monteleone G. Th17-related cytokines in inflammatory bowel diseases: friends or foes?. Curr. Mol.Med. 12, 592-597 (2012
3. Abraham C. & Cho J.H. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 60, 97-110 (2009
4. Abraham C. & Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm. Bowel Dis. 15, 1090-1100 (2009
5. Jostins L., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119-124 (2012
6. Franke A., et al.Genome-wide meta-analysis increases to 71 thenumber of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42, 1118-1125 (2010
7. Anderson C.A., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat. Genet. 43, 246-252 (2011
8. Glas J., et al. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am. J. Gastroenterol. 104, 1737-1744 (2009
9. Michel M.L., et al. Identification of an IL-17-producing NK1.1(neg) iNKTcell population involved in airway neutrophilia. J. Exp. Med. 204, 995-1001 (2007
10. Shibata K., Yamada H., Hara H., Kishihara K. & Yoshikai Y. Resident Vdelta1+ gammadelta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production. J. Immunol. 178, 4466-4472 (2007
11. Miossec P. & Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 11, 763-776 (2012
12. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9, 556-567 (2009
13. Song X., et al. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat. Immunol. 12, 1151-1158 (2011
14. Ramirez-Carrozzi V., et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat. Immunol. 12, 1159-1166 (2011
15. Reynolds J.M., Martinez G.J., Nallaparaju K.C., Chang S.H., Wang Y.H. & Dong C. Cutting edge: regulation of intestinal inflammation and barrier function by IL-17C. J. Immunol. 189, 4226-4230 (2012
16. Chang S.H., Reynolds J.M., Pappu B.P., Chen G., Martinez G.J. & Dong C. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 35, 611-621 (2011
17. Im E., Jung J. & Rhee S.H. Toll-like receptor 5 engagement induces interleukin-17C expression in intestinal epithelial cells. J. Interferon Cytokine Res. 32, 583-591 (2012
18. Friedrich M., Tillack C., Wollenberg A., Schauber J. & Brand S. IL-36gamma sustains a pro-inflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease. Inflamm. Bowel Dis. 20, 1891-1901 (2014
19. Cario E. & Podolsky D.K. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 68, 7010-7017 (2000
20. Ey B., et al. Loss of TLR2 worsens spontaneous colitis inMDR1Adeficiency through commensally induced pyroptosis. J. Immunol. 190, 5676-5688 (2013
21. Hueber W., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693-1700 (2012
22. Hueber W., et al. Effects of AIN457, a fully human antibody to interleukin- 17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52ra72 (2010
23. Laroui H., et al. Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon. PLoS One 7, e32084 (2012
24. Scheiffele F. & Fuss I.J. Induction of TNBS colitis in mice. Curr. Protoc. Immunol. Chapter 15 (Unit 15), 19 (2002
25. Nenci A., et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446, 557-561 (2007
26. Sturlan S., et al. Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis 22, 665-671 (2001
27. Powrie F., Coffman R.L. & Correa-Oliveira R. Transfer of CD4+ Tcells to C.B-17 SCID mice: a model to study Th1 and Th2 cell differentiation and regulation in vivo. Res. Immunol. 145, 347-353 (1994
28. Seok J., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. USA 110, 3507-3512 (2013
29. Mestas J. & Hughes C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731-2738 (2004
30. Johnston A., et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J. Immunol. 190, 2252-2262 (2013
31. Duerr R.H., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463 (2006
32. Glas J., et al. rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS One 2, e819 (2007
33. Schmechel S., et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm. Bowel Dis. 14, 204-212 (2008
34. Diegelmann J., et al. Intestinal DMBT1 expression is modulated by Crohn's disease-associated IL23R variants and by a DMBT1 variant which influences binding of the transcription factors CREB1 and ATF-2. PLoS One 8, e77773 (2013
35. Dambacher J., et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 58, 1207-1217 (2009
36. Brand S., et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G827-G838 (2006
37. Seiderer J., et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm. Bowel Dis. 14, 437-445 (2008
38. Brand S., et al. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J. Cell Biochem. 97, 709-723 (2006
39. Fujino S., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52, 65-70 (2003
40. Friedrich M., Diegelmann J., Beigel F. & Brand S. IL-17A alone weakly affects the transcriptome of intestinal epithelial cells but strongly modulates the TNF-alpha-induced expression of inflammatory mediators and inflammatory bowel disease susceptibility genes. Inflamm. Bowel Dis. 20, 1502-1515 (2014
41. Song X., et al. Alterations in the microbiota drive interleukin-17C production from intestinal epithelial cells to promote tumorigenesis. Immunity 40, 140-152 (2014
42. Zweibaum A., et al. Enterocytic differentiation of a subpopulation of the human colon tumor cell line HT-29 selected for growth in sugar-free medium and its inhibition by glucose. J. Cell Physiol. 122, 21-29 (1985
43. Hirota K., et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J. Exp. Med. 204, 2803-2812 (2007
44. Komatsu M., et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno- PCR. Clin. Chem. 47, 1297-1301 (2001
45. Kolby L., et al. A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am. J. Pathol. 158, 745-755 (2001
46. Lesuffleur T., et al. Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucussecreting HT-29 cell subpopulations. J. Cell Sci. 106 (Pt 3), 771-783 (1993
47. Qian Y., et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat. Immunol. 8, 247-256 (2007
48. Gaffen S.L. An overview of IL-17 function and signaling. Cytokine 43, 402-407 (2008
49. Matsushita K., et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 458, 1185-1190 (2009
50. Sun D., Novotny M., Bulek K., Liu C., Li X. & Hamilton T. Treatmentwith IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat. Immunol. 12, 853-860 (2011
51. Kinoshita S., Akira S. & Kishimoto T. A member of the C/EBP family, NF-IL6 beta, forms a heterodimer and transcriptionally synergizes with NF-IL6. Proc. Natl. Acad. Sci. USA 89, 1473-1476 (1992
52. Ruddy M.J., et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J. Biol. Chem. 279, 2559-2567 (2004
53. Sciola V., et al. Plasma chromogranin a in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 15, 867-871 (2009
54. Bonaz B.L. & Bernstein C.N. Brain-gut interactions in inflammatory bowel disease. Gastroenterology 144, 36-49 (2013
55. Gaffen S.L., Kramer J.M., Yu J.J. & Shen F. The IL-17 cytokine family. Vitam. Horm. 74, 255-282 (2006
56. Jurgens M., et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am. J. Gastroenterol. 105, 1811-1819 (2010
57. Tillack C., et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferongamma- expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 63, 567-577 (2014